Meilin Liao

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

Martin Reck, R. Kaiser, Anders Mellemgaard et al. · The Lancet Oncology · 2014 · 931 citations · Full text

Oncology, Nintedanib Versus Docetaxel, Lume-lung 1 +10

Detection and Dynamic Changes of <i>EGFR</i> Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

Tony Mok, Yi‐Long Wu, Jin Soo Lee et al. · Clinical Cancer Research · 2015 · 468 citations

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial

Yi‐Long Wu, Jin Soo Lee, Sumitra Thongprasert et al. · The Lancet Oncology · 2013 · 304 citations

Oncology, Medicine, Metronomic Therapy +6

Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares, Bonne Biesma, David F. Heigener et al. · Journal of Clinical Oncology · 2012 · 256 citations · Full text

Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

Tony Mok, Yi‐Long Wu, Chong‐Jen Yu et al. · Journal of Clinical Oncology · 2009 · 220 citations · Full text